Business
SARS: Sales up but losses deepen as order intake collapses; rights issue boosts cash but equity negative
SARS: Sales up but losses deepen as order intake collapses; rights issue boosts cash but equity negative
About this update from Sarsys Ab
SARSYS AB reported a slight increase in Q1 2025 sales but a wider loss, with order intake plunging and gross margin falling sharply. A rights issue improved liquidity, but negative equity and ongoing subsidiary reconstruction highlight continued financial risk.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.